SillaJen KRX:215600KOSDAQ
신라젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days35
DART filings, 7 days0
Articles tracked57since Sep 11
In Q2 2026, SillaJen reported revenue of ₩2.2bn, down 6.2% year on year, and an operating loss of ₩6.2bn. SillaJen (신라젠) appeared in 35 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 29 articles. The most common catalyst was clinical & approvals (18). It was most often mentioned alongside 글로벌테크놀로지.
Filing signals Clinical trial filing 4 quarters of losses Screener
SillaJen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.2bn | -6.2% | −₩6.2bn margin −275.5% | −₩5.5bn |
| Q1 2026 | ₩2.9bn | +146.4% | −₩5.6bn margin −198.1% | −₩4.9bn |
| Q4 2025 derived | ₩2.9bn | +90.7% | −₩8.2bn margin −280.2% | −₩7.8bn |
| Q3 2025 | ₩2.8bn | +114.2% | −₩6.1bn margin −222.0% | −₩5.9bn |
| Q2 2025 | ₩2.4bn | +196.5% | −₩6.2bn margin −258.7% | −₩5.5bn |
| Q1 2025 | ₩1.2bn | +282.9% | −₩5.1bn | −₩5.0bn |
| Q4 2024 derived | ₩1.5bn | – | −₩7.5bn | −₩6.9bn |
| Q3 2024 | ₩1.3bn | -24.9% | −₩7.6bn | −₩7.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
SillaJen top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest SillaJen news Korean headlines
-
Major신라젠 'BAL0891', 임상 1상서 병용요법 반응률 21.4% 확인
2 more on this story · 1 outlets
- 신라젠 BAL0891, 유럽종양학회서 항암효과 확인…병용군 반응률 21.4%이데일리 · Oct 26 15:11
- 신라젠 BAL0891, 유럽종양학회서 항암효과 확인…병용군 반응률 21.4%이데일리 · Oct 26 15:11
-
Major신라젠 BAL0891, 임상 1상 중간 결과 공개…병용군 ORR 21.4%
5 more on this story · 5 outlets
- 신라젠, 항암제 BAL0891 임상 중간 결과 유럽종양학회서 공개서울경제 · Oct 26 10:21
- 신라젠, ESMO 2026서 항암제 ‘BAL0891’ 1상 중간 결과 공개인사이트코리아 · Oct 26 11:13
- 신라젠, ESMO서 ‘BAL0891’ 임상 1상 중간 결과 공개쿠키뉴스 · Oct 26 14:23
- 신라젠, 'ESMO 2026'서 항암제 'BAL0891' 임상 중간 결과 공개보건신문 · Oct 26 16:45
- 신라젠, BAL0891 임상 중간 결과 ESMO 2026서 공개CNB뉴스 · Oct 26 17:58
-
신라젠, ESMO서 항암제 'BAL0891' 임상 성과 발표
1 more on this story · 1 outlets
- 신라젠, ESMO서 항암제 'BAL0891' 임상 중간 결과 발표아시아타임즈 · Oct 26 10:15
-
[ESMO 2026]이수진 신라젠 상무 “BAL0891, 완전관해 7개월 유지”
1 more on this story · 1 outlets
- [ESMO 2026]이수진 신라젠 상무 “BAL0891, 완전관해 7개월 유지”이데일리 · Oct 25 12:01
-
조국 "뉴이재명 '신라젠 재수사해 유시민 처벌' 황당한 주장"
1 more on this story · 1 outlets
- 조국 "뉴이재명들, 신라젠 재수사·유시민 처벌 주장…황당"뉴스토마토 · Oct 18 17:52